Absence of inducible costimulator (ICOS) on alloreactive T cells reduces graft-versus-host-disease while leaving graft-versus-tumor activity intact.

被引：0

作者：

Hubbard, VM ^{[1
]}

Eng, JM ^{[1
]}

Tjoe, KH ^{[1
]}

Ramirez-Montagut, T ^{[1
]}

Muriglan, SJ ^{[1
]}

Kochman, AA ^{[1
]}

Terwey, TH ^{[1
]}

Schiro, R ^{[1
]}

Alpdogan, O ^{[1
]}

van den Brink, MRM ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

BLOOD | 2004年 / 104卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

591

引用

页码：171A / 171A

页数：1

共 50 条

[31] Alloreactive memory T cells induce chronic graft-versus-host disease [J].

Zhang, Y ;

Hexner, E ;

Frank, D ;

Joe, G ;

Emerson, SG .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) :62-62

[32] Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation [J].

Schmaltz, C ;

Alpdogan, O ;

Muriglan, SJ ;

Kappel, BJ ;

Rotolo, JA ;

Ricchetti, ET ;

Greenberg, AS ;

Willis, LM ;

Murphy, GF ;

Crawford, JM ;

van den Brink, MRM .

BLOOD, 2003, 101 (06) :2440-2445

[33] Modulating Donor T Cell Graft-Versus-Host and Graft-Versus-Tumor Reactivity By Stat6 [J].

Fury, Hope ;

Guan, Xiaoqun ;

Atagozli, Tyler ;

Elliot, David E. ;

Blazar, Bruce R. ;

Ince, M. Nedim .

BLOOD, 2022, 140 :10261-10262

[34] Inducible Costimulator (ICOS) Is up-Regulated in Dogs with Graft Versus Host Disease and Graft Rejection Following Non-Identical Hematopoietic Cell Transplantation [J].

Graves, Scott Stoll ;

Sato, Masahiko ;

Loretz, Carol ;

Diane, Stone ;

Storb, Rainer .

BLOOD, 2012, 120 (21)

[35] Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib [J].

Sun, K ;

Welniak, LA ;

Panoskaltsis-Mortari, A ;

O'Shaughnessy, MJ ;

Liu, HY ;

Barao, I ;

Riordan, W ;

Sitcheran, R ;

Wysocki, C ;

Serody, JS ;

Blazar, BR ;

Sayers, TJ ;

Murphy, WJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (21) :8120-8125

[36] The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects [J].

Itamura, Hidekazu ;

Shindo, Takero ;

Tawara, Isao ;

Kubota, Yasushi ;

Kariya, Ryusho ;

Okada, Seiji ;

Komanduri, Krishna V. ;

Kimura, Shinya .

JCI INSIGHT, 2016, 1 (10)

[37] Graft-Versus-Tumor Effect In Patients with Graft-Versus-Host Disease Defined by NIH Consensus Criteria. [J].

Lee, Sung-Eun ;

Cho, Byung-Sik ;

Yahng, Seung-Ah ;

Eom, Ki-Seong ;

Kim, Yoo-Jin ;

Kim, Hee-Je ;

Lee, Seok ;

Min, Chang-Ki ;

Cho, Seok-Goo ;

Kim, Dong-Wook ;

Lee, Jong-Wook ;

Min, Woo-Sung ;

Park, Chong-Won .

BLOOD, 2010, 116 (21) :968-968

[38] LPAM (Alpha4 Beta7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease but not graft-versus-tumor effect. [J].

Kirovski, A ;

Feinman, JW ;

Alpdogan, O ;

Willis, LM ;

Eng, J ;

Kartono, TH ;

van den Brink, MRM .

BLOOD, 2002, 100 (11) :671A-672A

[39] Remodeling specific immunity by use of MHC-tetramers distinguishes Graft-Versus-Tumor activity from Graft-Versus-Host-Disease. [J].

Kappel, BJ ;

Pinilla-Ibarz, J ;

Kochman, AA ;

Eng, JM ;

Hubbard, VM ;

Leiner, IM ;

Pamer, EG ;

van den Brink, MRM ;

Scheinberg, DA .

BLOOD, 2005, 106 (11) :378A-378A

[40] Which T cells are needed for engraftment and graft-versus-tumor effect? [J].

Strober, S .

BLOOD, 1999, 94 (10) :79-79

← 1 2 3 4 5 →